Literature DB >> 17368524

A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET.

V Marchand1, J Graveleau, C Lanctin-Garcia, E Bourbouloux, B Bridji, I Resche, F Kraeber-Bodéré, C Rousseau.   

Abstract

BACKGROUND: PET/CT may be particularly useful to detect the primary cancer in paraneoplastic cerebellar degeneration (PCD) with anti-Yo which is most commonly associated with breast, ovarian and other gynecological cancers. CASE: A 60-year-old woman developed a PCD associated with anti-Yo antibodies in serum and cerebrospinal fluid. Conventional imaging was negative. FDG-PET showed an abnormal hot spot in the right ovarian area associated with lombo aortic lymph nodes. The diagnosis was confirmed by surgery as an ovarian adenocarcinoma.
CONCLUSION: In this case report, FDG-PET played a crucial role in detecting the unknown primary tumor in a patient with PCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368524     DOI: 10.1016/j.ygyno.2007.01.047

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

2.  Paraneoplastic Cerebellar Degeneration as Initial Presentation of Papillary Carcinoma of the Fallopian Tube: Evaluation and Usefulness of (18)F-FDG PET-CT. Case Report and Literature Review.

Authors:  Nayelli Ortega López; Digna Pachuca González; José Alfonso Rumoroso García; Juan Carlos García Reyna; Luis Felipe Alva López
Journal:  Nucl Med Mol Imaging       Date:  2012-10-15

Review 3.  Paraneoplastic neurological syndromes associated with ovarian tumors.

Authors:  Mikolaj Piotr Zaborowski; Marek Spaczynski; Ewa Nowak-Markwitz; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.